《美股業績》聯合健康(UNH.US)季績勝預期 新冠疫情成本被延後非緊急治療抵銷
美國醫療保險巨擘聯合健康(UnitedHealth)(UNH.US)公佈去年第四季度業績。收入按年升12.6%至737.43億美元,經營業務溢利55.41億美元,按年升57.5%。純利40.71億美元,按年升84%。每股季調純利4.26美元,經調整後爲4.48美元,高於市場預期的4.31美元。
公司表示,近期新冠疫情升溫導致的檢測及治療成本上漲,被非緊急醫療程序押後所抵銷,又指不少醫院應對新冠變種Omicron病人急增,把可選擇的醫療程序暫時擱置。
公司財務總監John Rex指出,過去數週醫療活動顯示初步護理求診減少約一成,專科求診跌幅更大。公司維持2022年經調整每股盈利預測,即介乎每股21.1至21.6美元,又指新冠變種Omicron個案的嚴重程度看來較低,病人留院日數較去年縮短。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.